Valeant Pharmaceuticals slashed its outlook for the fourth quarter and full year, and issued downbeat earnings guidance for 2016, as the drugmaker deals with the fallout from its relationship with specialty pharmacy Philidor.
from WSJ.com: US Business http://ift.tt/1O5yhna
via IFTTT
No comments:
Post a Comment